Atta Goudarzi, MD
Internal Medicine · Coos Bay, ORNPI 1790277549
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by GSK at 30.2% of the total. Reporting peaked in 2022 at $299 and has fallen 80.4% since, to $59 in 2025. Among internal medicine clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 40 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$199
- AbbVie$116
- Novartis$66
- Amgen$35
- Mallinckrodt Hospital Products Inc.$34
- Novo Nordisk$31
- plus $178 from 9 others
What the payments were for
- Food & beverage$658100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 14 | $199 |
| AbbVie | 6 | $116 |
| Novartis | 3 | $66 |
| Amgen | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Novo Nordisk | 2 | $31 |
| Bayer | 2 | $27 |
| Ultragenyx Pharmaceutical Inc. | 2 | $27 |
| AstraZeneca | 1 | $24 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Exact Sciences | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $11 |
How this compares
$658 in reported general payments places this provider in the 90th percentile of 1,363 internal medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $7,147 |
| Haloperidol | 12 | $409 |
| Omeprazole | 16 | $390 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $380 |
| Tamsulosin Hcl | 12 | $277 |
| Atorvastatin Calcium | 40 | $254 |
| Lisinopril | 19 | $205 |
| Trazodone Hcl | 13 | $166 |
| Amlodipine Besylate | 17 | $165 |
| Pantoprazole Sodium | 13 | $131 |
| Furosemide | 32 | $125 |
| Losartan Potassium | 13 | $93 |
| Carvedilol | 11 | $90 |
| Citalopram HbrCitalopram Hydrobromide | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Coos Bay
- Chad PfeferBeaverton$639K
- Pranav ChandrashekarPortland$81K
- Jonathan EdmistonBend$68K
- Jessica CastlePortland$66K
- Ellen Schiaffino PurvisGresham$66K
- Steven ShawWhite City$58K
- Stephen SpurgeonPortland$42K
- Jane BabiarzPortland$30K
- Andrew HarbisonPortland$29K
- Marc UemuraEugene$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.